[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:neuroendocrine-neoplasm":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":227,"states":236},"Neuroendocrine Neoplasm",36,29,[8,16,23,29,35,41,47,52,59,65,71,77,83,88,94,100,106,112,118,124,130,136,142,148,153,159,165,170,175,181,188,195,201,207,214,221],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05266612","Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:17:22.949982Z","2026-05-05T02:43:29.074063Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05997056","Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors",[20],"Phase 2","2026-08-03T02:34:16.012157Z","2026-05-05T02:43:28.658192Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06889493","SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)",[12],"2026-08-26T02:18:17.950264Z","2026-05-05T02:43:28.317139Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05746208","Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors",[20],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:28.183234Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05263050","Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors",[20],"2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.800671Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06406465","A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity",[20],"2026-08-26T02:18:22.309547Z","2026-05-05T02:43:27.055066Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":14,"content_modified":51},"NCT06926634","Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)",[20],"2026-05-05T02:35:31.706749Z",{"nct_id":53,"title":54,"phases":55,"status":13,"updated_at":57,"content_modified":58},"NCT02174549","Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer",[56],"Phase 1\u002FPhase 2","2026-08-26T02:16:35.654046Z","2026-05-05T02:43:28.986774Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT07151391","The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)",[20],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.826884Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT06577987","Safety\u002FEfficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies",[12],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:27.665400Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT07129252","A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors",[56],"2026-08-26T02:15:56.561131Z","2026-05-05T02:43:27.489197Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT07165132","Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.",[12],"2026-08-26T02:17:27.435233Z","2026-05-05T02:43:27.257230Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":14,"content_modified":87},"NCT06041516","A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors",[12],"2026-05-05T02:35:31.780901Z",{"nct_id":89,"title":90,"phases":91,"status":13,"updated_at":92,"content_modified":93},"NCT06055439","A Phase 1\u002F2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy",[56],"2026-08-26T02:18:54.586325Z","2026-05-05T02:35:31.753376Z",{"nct_id":95,"title":96,"phases":97,"status":13,"updated_at":98,"content_modified":99},"NCT06814496","Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors",[56],"2026-08-26T02:15:38.131683Z","2026-07-24T01:27:14.891188Z",{"nct_id":101,"title":102,"phases":103,"status":13,"updated_at":104,"content_modified":105},"NCT05636618","Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors",[56],"2026-08-26T02:17:03.534765Z","2026-07-05T05:32:16.808808Z",{"nct_id":107,"title":108,"phases":109,"status":13,"updated_at":110,"content_modified":111},"NCT04429087","A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3",[12],"2026-08-03T00:53:42.755927Z","2026-07-05T05:32:16.773103Z",{"nct_id":113,"title":114,"phases":115,"status":13,"updated_at":116,"content_modified":117},"NCT05000294","Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types",[56],"2026-08-26T02:17:17.791881Z","2026-06-06T00:48:49.531423Z",{"nct_id":119,"title":120,"phases":121,"status":13,"updated_at":122,"content_modified":123},"NCT01174121","Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer",[20],"2026-08-26T02:15:53.461103Z","2026-05-05T02:43:29.157617Z",{"nct_id":125,"title":126,"phases":127,"status":13,"updated_at":128,"content_modified":129},"NCT06805825","A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and\u002For Metastatic Solid Tumors Known to Express c-Kit",[12],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:27.274696Z",{"nct_id":131,"title":132,"phases":133,"status":13,"updated_at":134,"content_modified":135},"NCT06441331","Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors",[12],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:26.707134Z",{"nct_id":137,"title":138,"phases":139,"status":13,"updated_at":140,"content_modified":141},"NCT07284589","Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake",[20],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.807130Z",{"nct_id":143,"title":144,"phases":145,"status":13,"updated_at":146,"content_modified":147},"NCT06908629","Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors",[],"2026-08-26T02:19:29.119921Z","2026-05-05T02:43:26.962546Z",{"nct_id":149,"title":150,"phases":151,"status":13,"updated_at":146,"content_modified":152},"NCT05556473","F-Tryptophan PET\u002FCT in Human Cancers",[12],"2026-05-05T02:43:28.547796Z",{"nct_id":154,"title":155,"phases":156,"status":13,"updated_at":157,"content_modified":158},"NCT05237934","Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)",[],"2026-08-26T02:15:45.413021Z","2026-05-13T02:55:06.298667Z",{"nct_id":160,"title":161,"phases":162,"status":13,"updated_at":163,"content_modified":164},"NCT04090034","Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors",[],"2026-08-26T02:17:30.961790Z","2026-05-13T02:55:06.233960Z",{"nct_id":166,"title":167,"phases":168,"status":13,"updated_at":122,"content_modified":169},"NCT02402244","Project: Every Child for Younger Patients With Cancer",[],"2026-05-13T02:55:06.094469Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":57,"content_modified":174},"NCT02012699","Integrated Cancer Repository for Cancer Research",[],"2026-05-13T02:55:06.082833Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT04674267","Resilience and Equity in Aging, Cancer, and Health (REACH)",[],"2026-08-26T02:19:03.581490Z","2026-05-05T02:43:28.853116Z",{"nct_id":182,"title":183,"phases":184,"status":185,"updated_at":186,"content_modified":187},"NCT07661420","211At-MABG in Adults With Advanced Neuroendocrine Cancers",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:57.705506Z","2026-07-05T03:45:20.260334Z",{"nct_id":189,"title":190,"phases":191,"status":192,"updated_at":193,"content_modified":194},"NCT05160480","A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG",[],"ENROLLING_BY_INVITATION","2026-08-26T02:18:24.494016Z","2026-06-16T05:54:08.025989Z",{"nct_id":196,"title":197,"phases":198,"status":192,"updated_at":199,"content_modified":200},"NCT00923026","Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies",[],"2026-08-26T02:16:03.788292Z","2026-06-16T05:54:07.944666Z",{"nct_id":202,"title":203,"phases":204,"status":192,"updated_at":205,"content_modified":206},"NCT07542158","Ultralow Dose PET Imaging of 18F-FDOPA",[20],"2026-08-26T02:16:38.897933Z","2026-06-16T05:54:07.887224Z",{"nct_id":208,"title":209,"phases":210,"status":211,"updated_at":212,"content_modified":213},"NCT05271292","Chiauranib for Advanced Solid Malignant Tumors and Relapsed\u002FRefractory SCLC.",[56],"UNKNOWN","2026-08-03T02:02:26.137944Z","2026-05-05T02:43:27.436999Z",{"nct_id":215,"title":216,"phases":217,"status":218,"updated_at":219,"content_modified":220},"NCT03935893","Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:19:35.241322Z","2026-05-05T02:43:26.987294Z",{"nct_id":222,"title":223,"phases":224,"status":218,"updated_at":225,"content_modified":226},"NCT07118176","Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers",[12],"2026-08-03T03:24:20.303158Z","2026-05-05T02:43:28.732453Z",[228,232],{"biomarker":229,"count":230,"slug":231},"Somatostatin Receptor",5,"somatostatin-receptor",{"biomarker":233,"count":234,"slug":235},"MKI67 Gene",4,"mki67-gene",[237,241,244,247,250,254,258,262,265,268,271,274,277,280,283,286,289,292,295,298,301,305,308,311],{"state":238,"count":239,"slug":240},"California",9,"california",{"state":242,"count":239,"slug":243},"Maryland","maryland",{"state":245,"count":239,"slug":246},"Pennsylvania","pennsylvania",{"state":248,"count":239,"slug":249},"Texas","texas",{"state":251,"count":252,"slug":253},"Michigan",8,"michigan",{"state":255,"count":256,"slug":257},"Ohio",7,"ohio",{"state":259,"count":260,"slug":261},"Florida",6,"florida",{"state":263,"count":260,"slug":264},"Missouri","missouri",{"state":266,"count":260,"slug":267},"Tennessee","tennessee",{"state":269,"count":230,"slug":270},"Georgia","georgia",{"state":272,"count":230,"slug":273},"Massachusetts","massachusetts",{"state":275,"count":230,"slug":276},"Minnesota","minnesota",{"state":278,"count":230,"slug":279},"Utah","utah",{"state":281,"count":230,"slug":282},"Virginia","virginia",{"state":284,"count":234,"slug":285},"Arizona","arizona",{"state":287,"count":234,"slug":288},"Colorado","colorado",{"state":290,"count":234,"slug":291},"Illinois","illinois",{"state":293,"count":234,"slug":294},"Iowa","iowa",{"state":296,"count":234,"slug":297},"Kentucky","kentucky",{"state":299,"count":234,"slug":300},"Wisconsin","wisconsin",{"state":302,"count":303,"slug":304},"Connecticut",3,"connecticut",{"state":306,"count":303,"slug":307},"Nebraska","nebraska",{"state":309,"count":303,"slug":310},"Nevada","nevada",{"state":312,"count":303,"slug":313},"New Jersey","new-jersey"]